Nirmala Sitharaman
Expect the announcement of the high-powered committee on banking for Viksit Bharat soon
Expect the announcement of the high-powered committee on banking for Viksit Bharat soon
PSBs must move in the direction of the committee's report once it's out
NPAs are at the lowest ever in Indian banking history
Expect the announcement of the high-powered committee on banking for Viksit Bharat soon
Expect the announcement of the high-powered committee on banking for Viksit Bharat soon
PSBs must move in the direction of the committee's report once it's out
NPAs are at the lowest ever in Indian banking history
❤2🤣2
TCS: LAUNCHES AI PLATFORM FOR DRUG DEVELOPMENT 🤖💊
• TCS launches TCS ADD™ AgentHub, an enterprise-ready AI platform for drug development.
• Enables agentic AI at scale across R&D, clinical trials and pharmacovigilance.
• Up to 40% efficiency gains in clinical data management.
• Up to 30% reduction in study build effort.
• Up to 30% cost savings in safety case processing.
• AI agents can reduce quality control effort by up to 50%.
• TCS aims to become the world’s largest AI-led technology services company.
• TCS launches TCS ADD™ AgentHub, an enterprise-ready AI platform for drug development.
• Enables agentic AI at scale across R&D, clinical trials and pharmacovigilance.
• Up to 40% efficiency gains in clinical data management.
• Up to 30% reduction in study build effort.
• Up to 30% cost savings in safety case processing.
• AI agents can reduce quality control effort by up to 50%.
• TCS aims to become the world’s largest AI-led technology services company.
❤2😁1
SEBI CHAIRMAN ON CAS : MUTUAL FUNDS NOT FACING ISSUES AROUND CAS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
🍌4👍2❤1
SEBI CHAIRMAN ON CAS ; SAYS INDICATIVE PRICES ARE EXTREMELY IMPORTANT FOR TRADERS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
🍌6❤2👍2
SKY GOLD & DIAMONDS ENTERS MSCI INDIA DOMESTIC SMALL CAP INDEX
🌍 Sky Gold & Diamonds has been added to the MSCI India Domestic Small Cap Index in the latest MSCI index review.
💰 Company highlighted that it turned operating cash flow positive during the current quarter, improving working-capital discipline and quality of growth.
💎 Focus remains on lightweight and value-added jewellery, alongside expansion of its customer base and organised jewellery retail presence.
🏭 Its asset-light manufacturing model supports capacity scaling while maintaining capital efficiency.
🛡️ Company is also strengthening governance, financial processes and management systems as it prepares for a larger scale of operations.
🚀 Management expects the MSCI inclusion to broaden visibility within the institutional investment community and support its next phase of growth.
🟢 Impact: Positive — MSCI inclusion can improve institutional visibility, while positive operating cash flow strengthens the growth profile.
🌍 Sky Gold & Diamonds has been added to the MSCI India Domestic Small Cap Index in the latest MSCI index review.
💰 Company highlighted that it turned operating cash flow positive during the current quarter, improving working-capital discipline and quality of growth.
💎 Focus remains on lightweight and value-added jewellery, alongside expansion of its customer base and organised jewellery retail presence.
🏭 Its asset-light manufacturing model supports capacity scaling while maintaining capital efficiency.
🛡️ Company is also strengthening governance, financial processes and management systems as it prepares for a larger scale of operations.
🚀 Management expects the MSCI inclusion to broaden visibility within the institutional investment community and support its next phase of growth.
🟢 Impact: Positive — MSCI inclusion can improve institutional visibility, while positive operating cash flow strengthens the growth profile.
ZEE ENTERTAINMENT APPOINTS ASHISH MISHRA AS CHIEF MARKETING OFFICER
📌 Ashish Mishra appointed Chief Marketing Officer (CMO) effective August 17, 2026.
🎯 He will lead ZEE’s marketing and brand agenda, focusing on stronger consumer propositions and impactful campaigns.
🧠 Brings over two decades of experience across diverse industries and geographies, with expertise in building consumer-centric brands.
📺 Mandate includes deepening consumer engagement using insights, creativity and technology as media consumption evolves across platforms.
🤝 Mishra will be based in Mumbai and report directly to CEO Punit Goenka.
🔄 Current marketing head Kartik Mahadev will transition to a new role within the organisation, details to be announced later.
📌 Ashish Mishra appointed Chief Marketing Officer (CMO) effective August 17, 2026.
🎯 He will lead ZEE’s marketing and brand agenda, focusing on stronger consumer propositions and impactful campaigns.
🧠 Brings over two decades of experience across diverse industries and geographies, with expertise in building consumer-centric brands.
📺 Mandate includes deepening consumer engagement using insights, creativity and technology as media consumption evolves across platforms.
🤝 Mishra will be based in Mumbai and report directly to CEO Punit Goenka.
🔄 Current marketing head Kartik Mahadev will transition to a new role within the organisation, details to be announced later.
TCS LAUNCHES AGENTIC AI PLATFORM TO TRANSFORM DRUG DEVELOPMENT
💊 Launched TCS ADD™ AgentHub, an enterprise-ready Agentic AI platform for pharmaceutical drug development.
🧠 Enables pharma companies to deploy AI agents across clinical trials and pharmacovigilance, while maintaining regulatory compliance and auditability.
📈 Pilot deployments demonstrated up to 40% efficiency gains in clinical data management activities.
⚙️ Platform delivered up to 30% reduction in clinical study build effort and up to 30% cost savings in end-to-end safety case processing.
🔍 AI-powered safety agents can reduce quality-control effort by up to 50%.
👥 Uses a Human + AI operating model, embedding AI agents into enterprise workflows while humans retain governance and decision-making responsibility.
🟢 Impact: Positive — strengthens TCS’s AI-led healthcare offerings and expands its opportunity in global pharma R&D.
💊 Launched TCS ADD™ AgentHub, an enterprise-ready Agentic AI platform for pharmaceutical drug development.
🧠 Enables pharma companies to deploy AI agents across clinical trials and pharmacovigilance, while maintaining regulatory compliance and auditability.
📈 Pilot deployments demonstrated up to 40% efficiency gains in clinical data management activities.
⚙️ Platform delivered up to 30% reduction in clinical study build effort and up to 30% cost savings in end-to-end safety case processing.
🔍 AI-powered safety agents can reduce quality-control effort by up to 50%.
👥 Uses a Human + AI operating model, embedding AI agents into enterprise workflows while humans retain governance and decision-making responsibility.
🟢 Impact: Positive — strengthens TCS’s AI-led healthcare offerings and expands its opportunity in global pharma R&D.
❤2
EFC : CO EXPANDS PUNE FOOTPRINT WITH 95,897 SQ. FT. MANAGED OFFICE FACILITY
📍 Leased an entire A+ category building at Koregaon Park Annex, Pune, spanning 95,897 sq. ft.
💰 5-year lease carries projected revenue potential of over ₹70 crore.
🪑 New facility will add 2,000+ seats to EFC’s managed office portfolio.
⚙️ Full-building control enables better space utilisation, branding, customer experience and margin optimisation.
🚀 Expansion strengthens EFC’s Pune platform amid growing enterprise demand for scalable managed workspaces.
🔗 Along with the recent Ultrafresh acquisition, EFC is strengthening its integrated REaaS verticals across Managed Offices, Design & Build and Furniture Manufacturing.
🟢 Impact: Positive — capacity addition and ₹70+ crore revenue potential improve growth visibility.
📍 Leased an entire A+ category building at Koregaon Park Annex, Pune, spanning 95,897 sq. ft.
💰 5-year lease carries projected revenue potential of over ₹70 crore.
🪑 New facility will add 2,000+ seats to EFC’s managed office portfolio.
⚙️ Full-building control enables better space utilisation, branding, customer experience and margin optimisation.
🚀 Expansion strengthens EFC’s Pune platform amid growing enterprise demand for scalable managed workspaces.
🔗 Along with the recent Ultrafresh acquisition, EFC is strengthening its integrated REaaS verticals across Managed Offices, Design & Build and Furniture Manufacturing.
🟢 Impact: Positive — capacity addition and ₹70+ crore revenue potential improve growth visibility.
❤1
L&T SECURES ₹15,000+ CR ULTRA-MEGA OFFSHORE ORDER IN MIDDLE EAST
🌊 L&T Energy Hydrocarbon Offshore has secured an Ultra-Mega order worth over ₹15,000 crore from a prestigious Middle East client.
🏗️ Project involves development of multiple offshore facilities, covering engineering, procurement, construction, installation & commissioning (EPCIC).
🏭 Significant fabrication work will be executed at L&T’s integrated manufacturing and fabrication facilities.
🌍 Order further strengthens L&T’s long-standing presence in the Middle East offshore energy market.
⚡ Management termed it one of the most significant offshore developments currently underway in the Middle East, driven by growing investments to meet future energy demand.
🟢 Impact: Strong Positive — major order boosts L&T’s order book and provides strong long-term revenue visibility.
🌊 L&T Energy Hydrocarbon Offshore has secured an Ultra-Mega order worth over ₹15,000 crore from a prestigious Middle East client.
🏗️ Project involves development of multiple offshore facilities, covering engineering, procurement, construction, installation & commissioning (EPCIC).
🏭 Significant fabrication work will be executed at L&T’s integrated manufacturing and fabrication facilities.
🌍 Order further strengthens L&T’s long-standing presence in the Middle East offshore energy market.
⚡ Management termed it one of the most significant offshore developments currently underway in the Middle East, driven by growing investments to meet future energy demand.
🟢 Impact: Strong Positive — major order boosts L&T’s order book and provides strong long-term revenue visibility.
❤2
TRUALT BIOENERGY TO NDTVProfit (KYC)
India Will Face Sugar Shortage This Year
Won't See Much Impact On Co Operations (On Uneven Monsoon)
Will Be Able To Fund Capex Via Internal Accruals
Don't Have Plans To Raise Funds Right Now
Expect To Increase Capacity Utilisation To 80%
Expect To Get Incentive Package From State Govt
Have Already Received Subsidy From Govt
Will Be Commissioning 9 CBG Plants
CBG Has Been A Big Opportunity For Co
India Will Face Sugar Shortage This Year
Won't See Much Impact On Co Operations (On Uneven Monsoon)
Will Be Able To Fund Capex Via Internal Accruals
Don't Have Plans To Raise Funds Right Now
Expect To Increase Capacity Utilisation To 80%
Expect To Get Incentive Package From State Govt
Have Already Received Subsidy From Govt
Will Be Commissioning 9 CBG Plants
CBG Has Been A Big Opportunity For Co
❤1🍌1
SEBI CHAIRMAN ON CAS
INDICATIVE PRICES ARE EXTREMELY IMPORTANT FOR TRADERS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
MUTUAL FUNDS NOT FACING ISSUES AROUND CAS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
INDICATIVE PRICES ARE EXTREMELY IMPORTANT FOR TRADERS
INCREASED PARTICIPATION WILL IMPROVE CAS
WILL LOOK AT IDENTIFYING PROBLEMS ON THE PMS FRONT FOR CAS
MUTUAL FUNDS NOT FACING ISSUES AROUND CAS
CAS IS A MAJOR STRUCTURAL REFORM
CAS IS SEEING SOME INITIAL TEETHING PROBLEMS
🍌3👍2🖕2
CLEAN MAX ENVIRONMENTAL ENERGY — STAKE SALE UPDATE ⚡
• Approved sale of 26% stake in Clean Max Muoi Pvt Ltd to Relaxo Footwears Ltd for ₹26,000
• Approved sale of 49% stake in Clean Max Chin Pvt Ltd to VVDN Technologies Pvt Ltd for ₹49,000
• Transactions expected to be completed by 30 Oct 2026
• Both subsidiaries were incorporated in June 2026 and have not contributed to financials
• Buyers are not related parties
• Approved sale of 26% stake in Clean Max Muoi Pvt Ltd to Relaxo Footwears Ltd for ₹26,000
• Approved sale of 49% stake in Clean Max Chin Pvt Ltd to VVDN Technologies Pvt Ltd for ₹49,000
• Transactions expected to be completed by 30 Oct 2026
• Both subsidiaries were incorporated in June 2026 and have not contributed to financials
• Buyers are not related parties
STRAIT OF HORMUZ SHIPPING GRINDS TO A HALT AHEAD OF U.S.-IRAN CEASEFIRE EXPIRY
👍1
APOLLO MICRO:
Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
Bazaar.Update📊
APOLLO MICRO: Company has been awarded orders worth INR 80.83 cr by Defence PSUs, State Governments and Private Industries.
APOLLO MICRO SYSTEMS: ₹80.84 CR ORDER WINS 🚀
• Apollo Micro Systems secures orders worth ₹808.38 Mn (~₹80.84 Cr)
• Orders received from Defence PSUs, State Governments and Private Industries
• Order wins are part of the company’s ordinary course of business
• Apollo Micro Systems secures orders worth ₹808.38 Mn (~₹80.84 Cr)
• Orders received from Defence PSUs, State Governments and Private Industries
• Order wins are part of the company’s ordinary course of business
IRANIAN FOREIGN MINISTRY:
NO TALKS HAVE BEGUN DUE TO WASHINGTON'S VIOLATION OF THE MEMORANDUM OF UNDERSTANDING
NO TALKS HAVE BEGUN DUE TO WASHINGTON'S VIOLATION OF THE MEMORANDUM OF UNDERSTANDING
ICICI SECURITIES — BROKERAGE VIEW 📊
• Brigade Enterprises — BUY | Target ₹885
• GMR Airports — HOLD | Target ₹99 ↑ from ₹93
• Honasa Consumer — BUY | Target ₹720 ↑ from ₹600
• VA Tech Wabag — BUY | Target ₹2,410 ↑ from ₹1,680
• Max Healthcare — BUY | Target ₹1,275 ↑ from ₹1,215
• Page Industries — REDUCE | Target ₹31,500
• Indiqube Spaces — BUY | Target ₹263 | Upside ~42%
Key highlights: Positive stance on Brigade, Honasa, VA Tech Wabag, Max Healthcare & Indiqube; cautious on GMR Airports and Page Industries.
• Brigade Enterprises — BUY | Target ₹885
• GMR Airports — HOLD | Target ₹99 ↑ from ₹93
• Honasa Consumer — BUY | Target ₹720 ↑ from ₹600
• VA Tech Wabag — BUY | Target ₹2,410 ↑ from ₹1,680
• Max Healthcare — BUY | Target ₹1,275 ↑ from ₹1,215
• Page Industries — REDUCE | Target ₹31,500
• Indiqube Spaces — BUY | Target ₹263 | Upside ~42%
Key highlights: Positive stance on Brigade, Honasa, VA Tech Wabag, Max Healthcare & Indiqube; cautious on GMR Airports and Page Industries.
❤1
ANUPAM RASAYAN; CO UPGRADED FY27 REVENUE GROWTH GUIDANCE TO 30 % + FROM 20-25 % EARLIER 🟢🟢
❤1
LUPIN GETS USFDA FINAL APPROVAL FOR PITOLISANT TABLETS
🇺🇸 Lupin receives final approval from the USFDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
💊 The tablets are approved as bioequivalent to Wakix® for the indications covered under the approved labeling.
📋 Approval has been granted for Lupin’s Abbreviated New Drug Application (ANDA).
🎯 The approval allows Lupin to participate in the US market for the Pitolisant generic opportunity.
📈 Adds another approved product to Lupin’s US portfolio and strengthens its presence in complex/specialty generics.
🟢 Impact: Positive — USFDA approval expands Lupin’s US product portfolio and creates a new commercial opportunity.
🇺🇸 Lupin receives final approval from the USFDA for Pitolisant Tablets in 4.45 mg and 17.8 mg strengths.
💊 The tablets are approved as bioequivalent to Wakix® for the indications covered under the approved labeling.
📋 Approval has been granted for Lupin’s Abbreviated New Drug Application (ANDA).
🎯 The approval allows Lupin to participate in the US market for the Pitolisant generic opportunity.
📈 Adds another approved product to Lupin’s US portfolio and strengthens its presence in complex/specialty generics.
🟢 Impact: Positive — USFDA approval expands Lupin’s US product portfolio and creates a new commercial opportunity.
❤1
ANAND RATHI ON SUDARSHAN CHEMICAL
BUY | Target: ₹1,450 (Earlier ₹1,350)
Strong Q1 FY27 — Revenue ₹2,640 Cr, +5.4% YoY; adjusted EBITDA at ₹260 Cr.
Heubach margin recovery drives performance; EBITDA at ₹146 Cr with 7.4% margin.
FY27 guidance maintained at ₹9,800–10,200 Cr revenue & ₹800 Cr EBITDA.
FY29 target: ₹12,000–14,000 Cr revenue & ₹1,400–1,500 Cr EBITDA, with net-cash ambition.
Net debt reduced sharply to ₹530 Cr.
Raises FY27E/FY28E EBITDA estimates by 7.5%/2.3% on stronger integration benefits.
Further upside expected from procurement, manufacturing, SAP & SG&A synergies.
Target raised to ₹1,450 from ₹1,350, based on 11.2x FY28E EV/EBITDA.
BUY | Target: ₹1,450 (Earlier ₹1,350)
Strong Q1 FY27 — Revenue ₹2,640 Cr, +5.4% YoY; adjusted EBITDA at ₹260 Cr.
Heubach margin recovery drives performance; EBITDA at ₹146 Cr with 7.4% margin.
FY27 guidance maintained at ₹9,800–10,200 Cr revenue & ₹800 Cr EBITDA.
FY29 target: ₹12,000–14,000 Cr revenue & ₹1,400–1,500 Cr EBITDA, with net-cash ambition.
Net debt reduced sharply to ₹530 Cr.
Raises FY27E/FY28E EBITDA estimates by 7.5%/2.3% on stronger integration benefits.
Further upside expected from procurement, manufacturing, SAP & SG&A synergies.
Target raised to ₹1,450 from ₹1,350, based on 11.2x FY28E EV/EBITDA.